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Summary
Background The United Nations Sustainable Development Goal for health (SDG3) poses complex challenges for 
signatory countries that will require clear roadmaps to set priorities over the next 15 years. Building upon the work of 
the Commission on Investing in Health and published estimates of feasible global mortality SDG3 targets, we 
analysed Mexico’s mortality to assess the feasibility of reducing premature (0–69 years) mortality and propose a path 
to meet SDG3.
Methods We developed a baseline scenario applying 2010 age-speciﬁ c and cause-speciﬁ c mortality rates from the 
Mexican National Institute of Statistics and Geography (INEGI) to the 2030 UN Population Division (UNPD) 
population projections. In a second scenario, INEGI age-speciﬁ c and cause-speciﬁ c trends in death rates from 2000 to 
2014 were projected to 2030 and adjusted to match the UNPD 2030 mortality projections. A third scenario assumed a 
40% reduction in premature deaths across all ages and causes. By comparing these scenarios we quantiﬁ ed shortfalls 
in mortality reductions by age group and cause, and forecasted life expectancy pathways for Mexico to converge to 
better performing countries.
Findings UNPD-projected death rates yield a 25·9% reduction of premature mortality for Mexico. Accelerated 
reductions in adult mortality are necessary to reach a 40% reduction by 2030. Mortality declines aggregated across all 
age groups mask uneven gains across health disorders. Injuries, particularly road traﬃ  c accidents and homicides, are 
the main health challenge for young adults (aged 20–49 years)  whereas unabated diabetes mortality is the single most 
important health concern for older adults (aged 50–69 years).
Interpretation Urgent action is now required to control non-communicable diseases and reduce fatal injuries in 
Mexico, making a 40% reduction in premature mortality by 2030 feasible and putting Mexico back on a track of 
substantial life expectancy convergence with better performing countries. Our study provides a roadmap for setting 
national health priorities. Further analysis of the equity implications of following the suggested pathway remains a 
subject of future research.
Funding Mexico’s Ministry of Health, University of California, San Francisco, and Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
The Sustainable Development Goal for health (SDG3), 
adopted in September 2015, poses enormous challenges 
for all countries. Underpinning the overall objective to 
ensure healthy lives and promote wellbeing for all at all 
ages is a list of nine proposed targets (appendix).1 
Previous analyses undertaken to inform the SDG3 
targets provide evidence and proposals on target 
measurement and on what could be achievable at a global 
level based on observed country-speciﬁ c mortality.2–4 
These analyses show that country roadmaps to meet the 
SDG3 targets require a deeper analysis of speciﬁ c 
mortality trends and a pragmatic approach to linking 
targets with cost-eﬀ ective health interventions.3,5
Norheim and colleagues3 proposed an overarching 
quantitative target to support SDG3, namely to avoid 
40% of premature deaths by 2030 (premature deaths 
deﬁ ned as those of individuals younger than 70 years), 
which in turn would be the result of achieving a series of 
cause-speciﬁ c mortality subtargets (appendix).3 This 
ambitious undertaking can be reached only by clearly 
understanding the main causes of death by age group 
and the eﬀ ective interventions available to aﬀ ect those 
causes and their respective modiﬁ able risk factors. 
Countries have the opportunity to apply speciﬁ c and 
unique policy strategies targeted to their national health 
priorities and health system capabilities. Therefore, there 
are diﬀ erent ways to achieve a so-called 40 by 30 (40 × 30) 
overall target.
The Lancet Commission on Investing in Health6 
showed that a grand convergence in health (a reduction 
in avertable infectious, child, and maternal mortality 
down to universally low levels) could be achieved by 
2035. Since publication of its report titled Global Health 
2035, the Commission on Investing in Health working 
group has embarked on a series of consultations with 
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donor agencies and ministries of health and ﬁ nance to 
explore the implications for investments in health. One 
of these engagements has been with Mexico’s Ministry of 
Health on how to achieve SDG3 and get on track to 
converge to the better performing high-income countries 
(eg, among the Organization for Economic Cooperation 
and Development [OECD] countries of which Mexico is a 
member country).7 Mexico achieved major improvements 
in preventable maternal, newborn, and child health 
(MNCH), and substantial gains in life expectancy over 
the past 30 years. Despite this, Mexico is still behind 
most other OECD countries in several key areas ranging 
from comparatively high mortality from MNCH causes 
to the rising rates of non-communicable diseases (NCDs) 
and fatal injuries. As a result, life expectancy increase has 
slowed and is far from convergence with OECD countries 
(panel 1).8
In this study we project shortfalls, relative to a target of 
a 40% reduction of premature deaths, in age-speciﬁ c and 
cause-speciﬁ c mortality in Mexico by comparing three 
diﬀ erent mortality scenarios in 2030. Following the 
Commission on Investing in Health6 notion of grand 
convergence, we use these results to forecast life 
expectancy at birth and analyse Mexico’s potential to 
meet SDG3 and reach substantial convergence to better 
performing high-income countries.
Methods
Annual population estimates for 1990–2014 and 
projections based on the medium fertility variant for 
2015–30 were taken from the United Nations Population 
Division (UNPD) World Population Prospects 2015 
revision. The UNPD 5-year periods for mortality 
estimates were averaged to obtain midpoint estimates; 
these in turn were averaged to obtain estimates for every 
ﬁ fth year between 1990 and 2030. Intermediate years 
were then constructed assuming linear trends between 
these 5-year estimates. Population and deaths were 
grouped into ﬁ ve age groups: 0–4 years, 5–19 years, 
20–49 years, 50–69, and 70 years or more.
We used cause-speciﬁ c mortality estimates from the 
vital statistics reported by the National Institute of 
Statistics and Geography (INEGI). The INEGI 
cause-speciﬁ c mortality data were combined with UNPD 
mortality and population estimates and projections to 
construct three mortality scenarios. INEGI annual 
reported deaths between 1990 and 2014 were grouped into 
15 major categories representative of the most important 
disease clusters to obtain annual distributions of deaths 
by category across each of the ﬁ ve age groups (appendix). 
Deaths with an ill-deﬁ ned or otherwise unspeciﬁ ed cause 
(International Classiﬁ cation of Diseases, 10th Revision 
[ICD-10] codes R00–R99; 2·3% for 1990 and 1·7% for 
2014) or unspeciﬁ ed age (0·7% for 1990 and 0·5% for 
2014) were redistributed using the observed cause and 
age distributions, respectively. The resulting cause-speciﬁ c 
distributions for the ﬁ ve age groups were applied to the 
UNPD deaths and population ﬁ gures to produce adjusted 
ﬁ gures for deaths and death rates by age group and 
disease category from 1990 to 2014.
We constructed three scenarios with age-speciﬁ c and 
cause-speciﬁ c mortality estimates for 2030. The baseline 
scenario reﬂ ects changes in mortality exclusively 
associated with population growth and aging, and does 
not account for changes in mortality rates. Mortality rates 
were assumed to remain at the 2010 levels. Therefore, the 
2010 age-speciﬁ c and cause-speciﬁ c mortality rates were 
applied to the 2030 UNPD population prospects. We 
used 2010 as reference year to ensure consistency with 
the SDG3 and the work of Norheim and colleagues.3
 Research in context
Evidence before this study
Our work builds on the Lancet Commission on Investing in Health 
and Norheim and colleagues’ work. These sources provide a robust 
general framework for global convergence to explore how Mexico 
can reach Sustainable Development Goal 3 (SDG3). We build upon 
these analyses using United Nations Population Division age-
speciﬁ c mortality estimates and Mexican National Institute of 
Statistics and Geography age-speciﬁ c and cause-speciﬁ c mortality 
data, calibrating our results to the United Nations life expectancy 
projections for international comparability. We identiﬁ ed 
best-practice interventions based on the recommendations of 
international organisations and initiatives including WHO, the 
Organisation for Economic Co-operation and Development, and 
Disease Control Priorities, Third Edition.
Added value of this study
Our ﬁ ndings shed light on the underlying causes of mortality by 
age group that are limiting Mexico’s potential to achieve SDG3 
and thus, convergence in health status. Our study provides a 
country roadmap to identify and prioritise the health 
interventions that can support achievement of SDG3 and 
reduce the gap in life expectancy by 2030. Our approach can be 
used by other countries to operationalise SDG3.
Implications of this study
Our study can assist national authorities to prioritise areas of 
action with the greatest health impact and economic returns. 
Eﬀ ective priority setting is important in the face of budgetary 
constraints, and in evidence-based dialogue with other 
governmental authorities, such as the Ministry of Finance, and 
with other non-health sectors whose actions have an eﬀ ect on 
health (eg, transport, education, and violence prevention).
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The so-called inertial scenario projects cause-speciﬁ c 
mortality for 2030 assuming recent (2000–14) trends will 
continue so that expected progress is limited to merely 
letting policies and mortality trends follow their present 
path. With the statistical software R, we produced mortality 
rate projections for 2015–30 by disease category for each 
age group within the 0–69 years age range using a linear 
regression model based on the INEGI–UNPD adjusted 
2000–14 mortality rates. The projected mortality rates were 
applied to the UNPD population structure to produce 
estimates of deaths for 2015–30. These distributions across 
disease categories for all years and age groups were then 
adjusted to the UNPD 2015–30 medium-variant expected 
premature deaths for each age category to obtain cause-
speciﬁ c UNPD compatible estimates for deaths and death 
rates across the entire 1990–2030 time period.
We used trends for the 2000–14 period (instead of the 
1990–2014 period) to show the more recent evolution of 
mortality and to avoid potential biases from coding in 1998, 
when the ICD-10 was introduced in Mexico. Linear trends 
show a particularly good ﬁ t for most causes for the 2000–14 
period. In the case of homicides, however, the use of this 
timeframe leads to an overestimation of the expected 
number of deaths in this inertial scenario because of the 
large increase in the homicide rate between 2005 and 2011.34 
Nevertheless, we used a single timeframe for purposes of 
consistency. The underlying trends used to estimate this 
scenario are shown in ﬁ gure 1.
Panel 1: Mexico’s baseline for SDG3: progress in health status and future challenges9–38
Over the past 30 years, Mexico has achieved major 
improvements in maternal and child health, and gains in life 
expectancy. This is the result of a combination of factors, 
including strong health leadership, an emphasis on 
evidence-based policy implementation, and substantial and well 
targeted investment in cost-eﬀ ective health interventions. These 
interventions range from oral rehydration therapy, universal 
vaccination, clean water,and vector control to HIV/AIDS 
prevention and conditional cash transfers to promote regular 
clinic visits among the poorest population. The combined eﬀ ect 
of these measures helped to reduce maternal mortality from 
88·7 deaths per 100 000 livebirths in 1990 to 38·9 per 
100 000 livebirths in 2014, reaching 75% of the Millennium 
Development Goal (MDG) target for 2015. Under-5 child 
mortality fell 63·2% from 41·0 per 1000 livebirths in 1990 to 
15·1 in 2014, close to the corresponding MDG target of 13·7.
Despite these substantial gains, Mexico is behind OECD 
countries in several key areas. First, maternal, newborn, and 
child health (MNCH) performance is comparatively poor 
because several child health disorders and preventable diseases 
still account for an unacceptable share of total mortality. 
Neonatal mortality in Mexico is more than twice the rate of that 
in the USA (8·2 and 3·6 deaths per 1000 livebirths, respectively), 
the infant mortality rate is three times higher than the OECD 
average (13 and 3·8 deaths per 1000 livebirths in 2013, 
respectively), and the under-5 mortality rate is 16·8 compared 
with 6·6 in the USA. Poor MNCH performance is to a large 
extent a result of inequalities in income and other social 
determinants of health, as well as an absence of access to quality 
health services. Substantial inequalities in health across states 
persist, with poorer, southern states such as Oaxaca, Chiapas, 
and Guerrero falling behind in maternal and child health 
outcomes as well as in other indicators of health status, such as 
life expectancy.
Second, Mexico has a high and rising incidence of many 
non-communicable disease (NCDs) as a result of its aging 
population and an increased prevalence of related risk factors. 
NCDs now account for more than three-quarters of total 
mortality. Diabetes and cardiovascular disease alone account 
for 33·4% of adult mortality. The diabetes prevalence rate in 
adults aged older than 20 years is the highest in OECD 
countries, and twice the OECD average. The mortality rate from 
ischaemic heart disease is 1·2 times the OECD average. 
Although the rates of the most important related risk factors, 
overweight and obesity, are stabilising in many high-income 
countries, they continue to grow in Mexico. Of all OECD 
countries, Mexico, along with the USA, has the highest rates of 
overweight and obesity; prevalence in adults stood at more 
than 70% in 2012. Cancers are also emerging as a more 
frequent cause of death. In particular, breast cancer is the 
second leading cause of death (after diabetes) of women aged 
30–54 years. Similar to MNCH, regional inequalities in NCD 
rates are also substantial, although the geographical pattern of 
inequality is diﬀ erent. The northern and central regions and 
urban areas of Mexico have the highest rates of obesity and 
diabetes, and mortality from ischaemic heart disease. Death 
rates from NCDs tend to be higher, however, in low-income 
populations living in Mexico and incidence and mortality from 
cervical cancer is concentrated in the poorest states.
Third, Mexico has experienced a large increase in deaths due to 
injuries, particularly those that are violence-related. Although 
violent deaths have begun to decrease, they remain higher than 
in previous years. Violence-related mortality is highly 
concentrated in a few regions. The high rates of homicide in 
states like Durango, Chihuahua, and Guerrero are a major cause 
of the decreasing life expectancy for young men. Mortality due to 
accidents, particularly road traﬃ  c accidents, is also a substantial 
cause of preventable mortality.
As a result, the increase in life expectancy has slowed. Although 
Mexico gained on average 4·2 months per year in life expectancy 
between 1990 and 2000, from 2000 to 2015 it gained only 
2 months per year, and is far from converging with OECD 
countries. In 2015, life expectancy in Mexico reached 77 years, 
whereas in Japan (the best performer among OECD countries) 
it was 83·7 years and in the USA (a not-so-good performer) it 
was 79·2 years. 
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The SDG 40 × 30 scenario uses the baseline scenario as 
the departure point and projects the number of deaths 
and the resulting death rates consistent with a target of a 
40% reduction in overall premature mortality by 2030. 
We assumed a ﬂ at 40% rate of reduction across each age 
group in the 0–69 years age range and for each of the 
Figure 1: Mortality trends by major disease group, Mexico 1990–2014
Own estimates using combined data from the United Nations, Department of Economic and Social Aﬀ airs, Population Division, World Population Prospects, 2015 Revision, and the National Institute 
of Statistics and Geography, Statistics of mortality (INEGI; 1990–2014). Lines correspond to the 2000–2014 trends based on a simple linear regression. The shaded area around each ﬁ tted regression 
corresponds to the 95% CI. The list of ICD-9 and ICD-10 codes used to group deaths by major cause is included in the appendix.
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15 causes. We compared deaths and death rates between 
the SDG 40 × 30 estimated target and the inertial scenario 
to identify disease and age groups and resulting policy 
areas that are oﬀ -track and need scaling up of 
interventions to accelerate mortality reductions, and thus 
meet SDG3 targets. We calculated life expectancy based 
on the inertial and SDG 40 × 30 scenarios to assess 
convergence, with Japan as the best performer and the 
USA as an underperformer in the OECD. The USA is a 
particularly relevant reference for Mexico given its large 
population of Mexican origin and because it faces similar 
health challenges, most notably rising levels of 
overweight and obesity, as well as an ageing population.
In order to develop a complete proﬁ le of mortality in all 
age groups over time, we included results for the population 
aged 70 years and older. For this age group, the baseline and 
inertial scenarios follow the same logic as for the 0–69 years 
age group, except that the cause-speciﬁ c analysis was not 
undertaken. Baseline ﬁ gures reﬂ ect the demographic eﬀ ect 
of an aging population by keeping the 2010 mortality rate 
constant. Figures for the inertial scenario reﬂ ect the number 
of deaths as projected by UNPD, whereas the SDG 40 × 30 
scenario assumes the same mortality as the inertial scenario.
Role of the funding source
This study was partly supported by the Ministry of Health 
in Mexico, the Bill & Melinda Gates Foundation, and the 
University of California, San Francisco. The funders of 
this study had no role in the study design, or conduct, 
data collection, data management, data, analysis, data 
interpretation, or writing of the report. The corresponding 
author, as Under-Secretary of Health of Mexico from 
2014 to March, 2016, was responsible for the General 
Directorate of Health Information, which provides 
information on vital statistics in coordination with 
INEGI. The corresponding author had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
According to UNPD estimates, the Mexican population 
will age substantially in the coming decades and grow 
from 118·6 million people in 2010 to 148·1 million people 
in 2030. Under the baseline scenario, total mortality is 
projected to increase by 82% between 2010 and 2030 
(table 1). Nearly half of this increased mortality (46%) is a 
product of population aging, which is projected to result 
in more than 810 000 additional deaths by 2030. The 
remaining almost 202 000 additional deaths are the result 
of population growth. Most of the increased mortality 
occurs in older populations. Premature mortality 
(at age 0–69 years) is projected to increase by 49% and 
mortality at age 70 years and older is projected to increase 
by 122%.
The SDG 40 × 30 scenario seeks to avert 40% of yearly 
premature deaths in 2030 compared with the baseline 
scenario. However, UNPD projections for 2030 show that 
premature mortality will fall by only 26%, which is 
almost 64 000 deaths short of the SDG 40 × 30 target. 
Although mortality rates decreased for all age groups 
between 1990 and 2010 and are expected to drop further 
by 2030, the overall rate of decrease has slowed 
substantially and masks varying trends in mortality 
across age groups. From 1990 to 2010 the death rate for 
children aged 0–4 years decreased by 48%, whereas for 
older adults (aged 50–69 years) it decreased by only 29%. 
From 2010 to 2030, reductions in mortality across all ages 
will be slower than in the previous two decades; however, 
mortality reductions in children and adolescents 
(aged 0–19 years) will continue to outpace gains in adults 
(aged 20–69 years). Under the inertial scenario, the 
decrease in premature mortality will be 42% for children 
1990 2000 2010 2030
Deaths Rate* Deaths Rate* Deaths Rate* Baseline 
deaths
Inertial scenario SDG 40x30 target
Deaths† Rate* Change (%) 
vs 
baseline‡
Deaths§ Rate*
0–69 years 314 388 377·2 279 454 280·9 303 306 266·0 452 635 335 467 243·2 –25·9 271 581 196·9
   0–4 years 108 934 941·7 72 500 593·3 57 603 494·3 51 939 30 124 286·7 –42·0 31 163 296·6
   5–19 years 22 145 68·7 16 241 48·2 15 170 42·9 14 424 9642 28·6 –33·2 8654 25·7
   20–49 years 82 538 258·9 82 792 190·0 94 348 180·1 116 925 87 324 134·5 –25·3 70 155 108·1
   50–69 years 100 771 1315·4 107 921 1079·7 136 185 933·2 269 347 208 377 722·0 –22·6 161 608 559·9
70 years and 
over
149 190 6567·2 199 308 5965·6 252 149 5496·8 559 556 476 063 4676·6 –14·9 476 063 4676·6
Total 463 578 541·5 478 762 465·7 555 455 468·3 1 012 191 811 530 547·8 –19·8 747 644 504·7
Own estimates using data from the United Nations, Department of Economic and Social Aﬀ airs, Population Division, World Population Prospects, 2015 Revision. *All death 
rates are expressed per 100 000 population. †United Nations Population Division (UNPD) death estimates for 2030. ‡Percentage reduction of deaths under the estimated 
inertial scenario based on UNPD death estimates, relative to the baseline scenario. §Death rates for 2030 population assuming a ﬂ at 40% reduction in the baseline number of 
deaths for the 0–69 years age group and assuming the inertial rate for the 70 years and older age group.
Table 1: Deaths and death rates by age group in 1990, 2000, 2010, and three scenarios for 2030 
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aged 0–4 years and 33% for young people aged 5–19 years. 
By contrast, the decrease for adults aged 20–49 years will 
be 25% and for those aged 50–69 years it will be 23%.
The slower rates of decrease in adult mortality are of 
particular concern. Under the baseline scenario, 85% of 
premature deaths will occur in people aged 20–69 years, 
precisely where the least health gains are expected in the 
future. In fact, nearly all (98·5%) of the predicted 
shortfall in mortality reduction comparing the inertial 
with the SDG 40 × 30 target will be in those 
aged 20–69 years (about 17 000 excess deaths for those 
aged 20–49 years and 47 000 excess deaths for those 
aged 50–69 years).
Mortality trends by major cause of death further explain 
the mortality dynamics seen across age groups. Trends 
used to construct the inertial scenario are shown in 
ﬁ gure 1. In the baseline scenario, 13% of total premature 
mortality is associated with MNCH disorders and 
communicable diseases (table 2). By contrast, 70% is 
associated with NCDs, and 17% with injuries (see 
combined results by cause and age group in the 
appendix).
Childhood infectious diseases and adverse events 
associated with childbirth continue to represent an 
unﬁ nished health agenda. Nevertheless, mortality from 
communicable, perinatal, maternal, and nutritional 
causes shows the most impressive downward trends 
up to 2030. Under the inertial scenario, the SDG 
40 × 30 targets for MNCH disorders, as well as mortality 
targets for children and adolescents (aged 0–19 years), 
are expected to be met by a good margin (table 1). 
However, sustained eﬀ orts to ensure that recent trends 
continue for this cluster will be necessary to attain 
the target.
1990 2000 2010 2030
Deaths Rate* Deaths Rate* Deaths Rate* Baseline 
deaths
Inertial scenario SDG 40x30 target
Deaths† Rate* Change vs 
baseline 
(%)‡
Deaths§ Rate*
Ages 0–69 years 314 388 377·2 279 454 280·9 303 306 266·0 452 635 335 467 243·2 –25·9% 271 581 196·9
Communicable, perinatal, maternal, or 
nutritional causes
108 864 130·6 66 176 66·5 51 637 45·3 57 892 27 253 19·8 –52·9% 34 735 25·2
Newborn and child health (ages 0–4 years) 81 433 704·0 47 119 385·6 33 255 285·4 29 985 11 386 108·4 –62·0% 17 991 171·2
Asphyxia and birth trauma 19 572 169·2 19 028 155·7 13 574 116·5 12 239 3285 31·3 –73·2% 7343 69·9
Acute respiratory infections 16 866 145·8 6833 55·9 3949 33·9 3561 0 0·0 –100·0% 2137 20·3
Intestinal infections 18 308 158·3 4029 33·0 1450 12·4 1307 0 0·0 –100·0% 784 7·5
Perinatal and other nutritional and 
communicable causes
26 687 230·7 17 229 141·0 14 282 122·6 12 878 8101 77·1 –37·1% 7727 73·5
Maternal and other nutritional and 
communicable causes (ages 5–69 years)
27 431 38·2 19 057 21·8 18 382 18·0 27 907 15 867 12·5 –43·1% 16 744 13·1
Non-communicable diseases 147 562 177·1 163 493 164·4 191 589 168·0 316 871 244 198 177·0 –22·9% 190 123 137·8
Vascular, diabetes, and related disorders 72 714 87·3 84 816 85·3 103 574 90·8 183 561 137 831 99·9 –24·9% 110 137 79·8
Vascular 35 304 42·4 34 456 34·6 41 145 36·1 72 349 52 950 38·4 –26·8% 43 409 31·5
Diabetes 16 142 19·4 25 235 25·4 38 109 33·4 70 435 69 188 50·2 –1·8% 42 261 30·6
Cirrhosis and other chronic liver diseases 16 191 19·4 19 981 20·1 18 350 16·1 31 250 7729 5·6 –75·3% 18 750 13·6
Renal 5077 6·1 5144 5·2 5970 5·2 9527 7964 5·8 –16·4% 5716 4·1
Cancers 28 640 34·4 34 138 34·3 37 669 33·0 63 471 42 847 31·1 –32·5% 38 083 27·6
Other non-communicable diseases 46 208 55·4 44 539 44·8 50 346 44·2 69 839 63 521 46·0 –9·0% 41 903 30·4
Injuries 57 962 69·6 49 785 50·1 60 080 52·7 77 872 64 016 46·4 –17·8% 46 723 33·9
Homicides 14 972 18·0 10 709 10·8 22 618 19·8 28 946 37 828 27·4 30·7% 17 368 12·6
Non-road traﬃ  c injuries 27 138 32·6 22 114 22·2 19 265 16·9 25 208 9317 6·8 –63·0% 15 125 11·0
Road traﬃ  c injuries 13 918 16·7 13 565 13·6 13 977 12·3 18 271 10 530 7·6 –42·4% 10 963 7·9
Suicides 1934 2·3 3397 3·4 4220 3·7 5447 6341 4·6 16·4% 3268 2·4
Ages 70 years and over 149 190 6567·2 199 308 5965·6 252 149 5496·8 559 556 476 063 4676·6 –14·9% 476 063 4676·6
Total 463 578 541·5 478 762 465·7 555 455 468·3 1 012 191 811 530 547·8 –19·8% 747 644 504·7
Own estimates using combined data from the United Nations, Department of Economic and Social Aﬀ airs, Population Division, World Population Prospects, 2015 Revision, and the National Institute of Statistics 
and Geography (INEGI), Statistics of mortality (1990–2014). *All death rates are expressed per 100 000 population. †The estimated and adjusted number of deaths for 2030 use United Nations Population Division 
(UNPD) population projections and implied death rates for 2030 with linear regressions based on cause-speciﬁ c and age-speciﬁ c mortality rates for years 2000–14. ‡Percentage reduction of deaths under the 
estimated inertial scenario based on UNPD death estimates, relative to the baseline scenario. §Death rates for 2030 population assuming a flat 40% reduction in the baseline number of deaths across age groups. 
The list of the International Classiﬁ cation of Diseases, 9th Revision and the International Classiﬁ cation of Diseases, 10th Revision codes used to group deaths by major cause is included in the appendix.
Table 2: Premature deaths and death rates by cause in 1990, 2000, 2010, and three scenarios for 2030 
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A cluster of four major non-communicable disease 
groups, vascular disease (including cardiovascular 
diseases, stroke, and hypertensive diseases), diabetes, 
renal disease, and liver disease, will account for more 
than 40% of total premature deaths in the baseline 
scenario, maintaining their present position as a leading 
cause of premature mortality. From 1990 to 2010, the 
share of mortality from this cluster, relative to total 
premature deaths, increased from 72 714 (23·1%) to 
103 573 (34·1%), and deaths from these causes were 
1·4 times higher in 2010 than in 1990. Deaths from 
cancer also increased during this period, though their 
contribution to premature mortality increased less, from 
28 640 (9·1%) to 37 669 (12·4%).
The largest challenge and the greatest opportunity to 
meet the SDG 40 × 30 target therefore lies in reversing 
the trends for mortality from NCDs. The inertial scenario 
will fall short of this goal by about 54 000 deaths in 2030. 
Half of this shortfall results from the very small projected 
reduction in diabetes mortality. Under present trends, 
expected mortality from diabetes will nearly double by 
2030, and will be 1·6 times higher than the SDG 
40 × 30 target. Similar challenges exist for renal disease 
and a diverse set of other NCDs (such as non-congenital 
thyroid and other endocrine disorders, mental and 
behavioural disorders, or other nervous, eye, ear, 
respiratory, and digestive system illnesses). However, the 
expected death rates from vascular disease, cirrhosis and 
other chronic liver diseases, and cancers are projected to 
be more in line with the SDG 40 × 30 target.
Mortality due to injuries has remained constant as a 
share of premature mortality over the past two decades. 
In 2010, non-road traﬃ  c and road traﬃ  c injuries, 
homicides, and suicides accounted for 53·1% of all 
deaths in individuals aged 5–19 years, and homicides 
were the leading cause of premature deaths for young 
adults (aged 20–49 years; appendix). However, owing to 
large variations in mortality rates across all age groups, 
homicide remains the most diﬃ  cult cluster for which to 
predict trend behaviour over the next 15 years. 
Nevertheless, we ﬁ nd that homicides account for most of 
the projected shortfall in this cluster relative to the SDG 
40 × 30 target. Projected deaths under the inertial scenario 
for road traﬃ  c accidents are in line with a 40% reduction 
in mortality, but will certainly fall short if we consider the 
SDG3 target for road safety, which is a 50% reduction in 
road traﬃ  c deaths and injuries by 2020.
Mexico has the lowest life expectancy of all OECD 
countries and its present path is far from converging 
with better performing countries. From 2000 to 2013, the 
longevity gap between Mexico and the OECD average 
widened from 4 years to almost 6 years. Figure 2 shows 
past and projected trends for Japan (the best performer), 
the USA (underperformer), and Mexico, including the 
projected life expectancy under the inertial scenario 
(an additional 3·8 years) and the SDG 40 × 30 scenario 
(4·7 additional years), reaching 81·4 years by 2030.
In 2010, the diﬀ erence in life expectancy between 
Mexico (76·7 years) and Japan (84·2 years) was 7·5 years. 
To close this gap in life expectancy with Japan, Mexico 
would need to substantially accelerate the annual rate of 
increase in life expectancy. This is an ambitious goal 
because the increase in life expectancy between 2000 and 
2010 (2·3 years) was only two-thirds of that observed 
between 1990 and 2000 (3·5 years). A more reasonable 
goal for Mexico is to reach the United Nations estimate 
for life expectancy in the USA of 82·3 years by 2030.
By reviewing the age-speciﬁ c gains in mortality 
projected under the SDG 40 × 30 scenario, we can assess 
the causes and trends in life expectancy in Mexico and 
identify the major shortfalls in mortality reduction that 
will need to be addressed for Mexico to converge with the 
USA. The diﬀ erences in mortality rates by age group 
compared with the USA are presented in ﬁ gure 3. The 
age-speciﬁ c gains in mortality show that convergence 
can be achieved under the SDG 40 × 30 strategy if eﬀ orts 
are focused on the population aged 20–69 years. For older 
adults aged 50–69 years, mortality can even improve 
beyond the 2030 projection for the USA. Convergence for 
the young population would require substantial eﬀ orts 
that go beyond the SDG 40 × 30 target. The population 
aged older than 70 years is near convergence under 
UNPD-projected mortality, our assumption for this 
group for the SDG 40 × 30 scenario. However, given the 
high share of deaths in this group relative to total 
mortality, a greater reduction in mortality rates for this 
population group could result in a major shift in life 
expectancy. As expected, younger populations are still 
most aﬀ ected by infectious diseases and childbirth 
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Figure 2: Mexico’s potential to converge in life expectancy by 2030
Japan and USA estimates are based on UNPD data. Mexico’s inertial forecast 
takes into account linear projections of trends in cause-speciﬁ c mortality rates 
and United Nations population projections. Mexico’s SDG 40 × 30 scenario 
considers an overall reduction of 40% in premature mortality (for individuals 
aged 0–69 years) by 2030. Own estimates using combined data from the United 
Nations, Department of Economic and Social Aﬀ airs, Population Division, World 
Population Prospects, 2015 Revision, and the National Institute of Statistics and 
Geography (INEGI), Statistics of mortality (1990–2014).
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mortality; homicides, non-road traﬃ  c injuries, and road 
traﬃ  c accidents aﬀ ect mostly adults aged 20–49 years, 
and NCDs, such as diabetes, take their highest toll in 
older adults (aged 50 years and older).
Discussion
To reduce premature mortality in Mexico by 40% by 2030 
will require implementation of cost-eﬀ ective health 
interventions, focusing on those age groups and health 
disorders in which inertial trends are projected to fall 
short of the SDG 40 × 30 target.  
Maternal, neonatal, and child mortality gains are a success 
story and an important contributor to past increases in life 
expectancy, yet there is room to ensure that the expected 
favourable trends in this area are sustained to meet the 
SDG3. Mortality for these disorders is very concentrated in 
low-income and underserved populations who need to be 
reached with quality services (panel 1).
Present coverage rates for antenatal care (98·6%) and 
facility-delivery (94·5%) are high, but the quality of these 
services will need to be improved and standardised to 
address the wide variation in state practices and reduce 
mortality.29,39–41 Eﬀ orts should focus on ensuring full 
adherence to WHO recommendations and clinical 
guidelines for antenatal and delivery care, including 
continuous care from early stages of pregnancy and 
compliance with caesarean best practices, especially 
focusing on the poorest areas of the country where 
deaths are highest.42–44
Improved access to neonatal care is also needed to 
reduce mortality in preterm babies. Focus should be 
placed on expanding adequate use of thermal care, 
continuous positive airway pressure therapy, surfactants 
for respiratory distress syndrome, oxygen therapy,43 
breastfeeding, and skin-to-skin care.45,46
To accelerate the reduction in mortality for the cluster 
of NCD deaths, we propose a three-pronged approach 
organised around the life cycle and stage of disease 
continuum, in line with WHO recommendations and 
universal health coverage goals.47
First, scaling up healthy lifestyle interventions that target 
underlying risk factors, such as economic incentives 
through taxation, is the most cost-eﬀ ective strategy, 
although its full eﬀ ect can only be seen in the long run. 
More rigorous ﬁ scal and regulatory policies for tobacco, 
sugar, salt, and alcohol consumption should be introduced, 
building on existing policies and knowledge. These policies 
are powerful levers for reduction of NCDs, increase of 
revenue that can be allocated to the health sector, and can 
also be in favour of poor or low-income populations.6,48,49 In 
Mexico, the tobacco tax rate is still low compared with other 
countries and could be doubled to avert new smokers, 
especially young people.50,51 In 2014, Mexico introduced a 
10% tax on sugar-sweetened non-alcoholic beverages and 
an 8% tax on high-calorie processed foods. Although the 
tax was not earmarked to health and thus the budget for 
preventive care did not increase as a result, taxes increased 
prices and early evidence shows that consumption patterns 
are starting to change as a result.52,53 Improving the 
availability and consumption of drinking water could help 
to decrease consumption of sugar-sweetened beverages. 
Finally, reducing sodium consumption, such as through 
regulating processed food, can be a cost-eﬀ ective 
intervention to reduce cardiovascular mortality.24,47,54
A second set of NCD-related priorities are associated 
with more eﬀ ective primary care-based prevention and 
early detection interventions combined with disease 
management to avoid further progression, ensure access 
to treatment and disease control, and ensure 
post-treatment follow-up to prevent recurrence. The 
mortality related to diabetes shows the present situation 
and the urgency of action. Within OECD countries, 
Mexico has one of the highest rates of hospital admissions 
due to uncontrolled diabetes, twice the OECD average.17 
Poor access to, and poor performance of, primary care are 
to blame, including limited access to drugs and supplies 
and inadequate monitoring of clinical markers. Only 
24% of patients with diabetes are considered to be under 
adequate control, and 49% of the diabetic population is 
unaware of their condition.29,55 However, diabetes tends to 
be overused as the underlying cause of death for cardio-
metabolic disease and its complications, thus the need for 
better classiﬁ cation of all causes of deaths is another 
pending challenge. Similarly, estimates suggest that more 
than 47% of adults with high blood pressure are unaware 
of their condition, and among adults aware of being 
hypertensive, only 74% were under treatment and only 
51% had their blood pressure under control.56
A third set of priorities around NCDs that can deliver 
substantial short-term improvements in mortality are 
related to improved access to quality care for hospital-
based treatment for patients, and timely emergency care. 
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Even with great improvements in primary care, patients 
with vascular disorders or diabetes will continue to need 
access to hospital treatment and emergency care. There 
is insuﬃ  cient access to hospital care, aggravated by the 
ineﬃ  cient allocation of scarce hospital beds across 
patient needs.16,17 Hospital admissions for congestive 
heart failure in adults are the lowest in OECD countries.16 
Furthermore, uptake of eﬀ ective procedures that are 
standard practice in other countries is comparatively low, 
such as coronary artery bypass grafting.24 Increased use 
of appropriate hospital-based interventions is therefore 
strongly recommended.
Chronic kidney disease prevention, including the 
control of associated risk factors, is feasible. In the short 
term, priority should be given to slow the progression 
towards end-stage renal failure in patients with chronic 
kidney disease. For more advanced disease stages, 
increased access to dialysis and kidney transplants is the 
only option. Both interventions are quite costly although 
transplants are more cost-eﬀ ective, and evidence 
suggests that promoting transplants is desirable.24 
Treatment for end-stage renal disease in Mexico is still 
restricted and insurance coverage for treatment varies. 
Increased access needs to be paired with standardised 
practice, especially across the diﬀ erent alternatives for 
dialysis treatment. Donor programmes also need to be 
scaled up to meet the demand for kidneys.
Finally, although projected mortality from cancer is 
in line with the SDG3 target, further reductions in 
premature mortality are both desirable and feasible. In 
particular, there are several cancers for which cost-
eﬀ ective interventions are available and that are highly 
preventable or curable when detected early. Access to 
treatment needs to be aligned with strengthened early 
detection and prevention at the primary care level to 
avoid heavily spending on very costly interventions that 
are likely to be ineﬀ ective due to the advanced stage of 
detection. In addition to interventions to reduce cancer 
risk factors, particularly smoking, priority interventions 
should include expanded coverage of human papilloma 
Panel 2: Systemic challenges and opportunities to meet SDG360–67
Despite great eﬀ orts to increase public health spending, 
Mexico still spends less on health, as a proportion of gross 
domestic product (GDP), than other OECD countries. In 2013, 
Mexico’s total health expenditure was 6·2% of GDP, compared 
with the 8·9% OECD average. The public component of health 
expenditures is also substantially lower in Mexico, at 3·2% of 
GDP, compared with 6·5% in OECD countries, and out-of-pocket 
spending on health remains relatively high, making up 44·7% of 
total health expenditures in 2013 compared with 20% in OECD 
countries. Despite the expansion of health coverage through 
Seguro Popular (a public health insurance in Mexico) in the past 
decade, new eﬀ orts are neeeded not only to optimise returns on 
health investments but also to further improve the provision of 
ﬁ nancial risk protection.
At the same time, the country faces challenges in cost-
containment, not least because high rates of chronic illness 
come at substantial economic cost. Costs associated with the 
primary obesity-related diseases are projected to increase from 
US$880 million in 2013 to $1·2 billion by 2030. The costs (direct 
and indirect) associated with diabetes and its complications 
account for 2·25% of Mexico’s GDP. And in 2008, the annual 
cost of treatment for four obesity-related diseases (colorectal 
malignant tumours, malignant breast tumours, diabetes, and 
cardiovascular disease) is estimated to amount to a third of the 
country’s public health-care budget. Unless eﬀ ective glycaemic 
control among patients with diabetes becomes commonplace, 
fatal diabetic complications will continue being not only a 
health burden, but also an economic one.
In these circumstances, to meet the SDG3 targets, Mexico will 
need to increase its health investments. In line with 
international targets, this would mean reaching a level for 
government funding of 5% of GDP. But Mexico will also need to 
improve eﬃ  ciency, which requires ﬁ nancial and institutional 
reform and political will to ensure that resources are allocated 
in an optimum way. Optimum allocation will require changes in 
how resources are distributed across diﬀ erent parts of the 
country, as well as how they are allocated across institutions, 
interventions, and health-care providers. Attention should be 
focused on poor-performing states and on the emerging health 
crisis of NCDs and injuries. A so-called whole health systems 
universal health coverage approach that includes all health 
system functions and major actors, not limited to Seguro 
Popular or health insurance for ﬁ nancial protection alone, will 
also be needed.
Dealing with NCDs and injuries presents substantial operational 
and ﬁ nancial challenges for the health system, as well as 
opportunities to achieve SDG3 following a 40x30 strategy. 
Mexico will need to expand health insurance packages beyond 
WHO’s suggested best-buy interventions for NCDs to include 
a much wider range of early detection, treatment, and 
management of these diseases. Strengthening primary care 
would be the best route for the system to maintain a focus on 
both maternal and child disorders while dealing with NCDs and 
their associated risk factors. The eﬀ ective treatment of NCDs 
will require restructuring service delivery in a way that enables 
not only a shift of attention towards prevention, but also a 
dramatic move from episodic care to continuous care for 
chronic disorders, including survivorship and palliative care.
Mexico’s path to SDG 40x30 should be anchored in both 
deepening entitlements to a broader package of care services 
with ﬁ nancial protection while at the same time extending the 
gains achieved in MNCH with core eﬀ orts in primary care. This 
holistic approach echoes the SDGs in maximising the synergies 
between health gains and poverty reduction. 
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virus vaccination and the scale-up of screening, early 
detection, and treatment in early stages of cervical, 
breast, and colorectal cancer.57
Reduction of injury-related mortality will result in the 
greatest health gains in older children (aged 5–19 years) 
and young adults (aged 20–49 years). High mortality 
rates in children and young adults help to explain the 
present life expectancy diﬀ erence between Mexico and 
other OECD countries, and are a contributing factor to 
the decreases in life expectancy gains observed between 
2000 and 2010.
With increased motorisation associated with economic 
development, large eﬀ orts will be needed to meet the 
SDG3 target for road safety (a 50% reduction in road 
traﬃ  c deaths and injuries by 2020). Several eﬀ ective 
policy options exist that can substantially reduce 
mortality, including setting and enforcement of speed 
limits, seatbelt requirements, drunk-driving laws, 
motorcyclists’ helmet use and child safety restraint use, 
and improved vehicle safety standards and safer roads 
that account for the needs of all users (including 
pedestrians).58,59 However, Mexico falls behind other 
countries in most of these measures.35,59 Road safety 
legislation and enforcement is largely the responsibility 
of state and municipal authorities, and only a small 
number of states have legislation supporting these core 
preventive measures. Jalisco and Mexico City have much 
stronger legislation and enforcement and oﬀ er a positive 
example that could be used to design a national 
regulatory framework.59
Mexico experienced a large increase in homicide-related 
mortality rates during 2005–11 as a consequence of the 
national policy to ﬁ ght drug traﬃ  c. The increase in 
fatalities explains the large reduction in life expectancy 
for men, especially in northern states such as Chihuahua, 
Sinaloa and Durango, and Guerrero and Nayarit, and a 
slowdown in the increase in life expectancy for women.34 
Because many factors contribute to violence, tackling 
mortality from homicides requires an intersectoral 
approach. In terms of actions more directly amenable to 
health-sector leadership, and its coordination with other 
sectors, we propose that measures to reduce alcohol and 
drug consumption, as well as to promote healthy 
environments at the community level, are included in a 
broad strategy to reduce mortality from this cause.
To achieve convergence and meet the SDG3 targets, 
several systemic challenges will need to be addressed. 
The main challenge for Mexico’s health system is how to 
organise the ﬁ nance and delivery systems around these 
interventions in a way that ensures eﬀ ective access and 
high quality, and standardised performance across the 
country (panel 2). In addition, addressing mortality due to 
the leading risk factors (high body-mass index, high 
fasting plasma glucose, alcohol and tobacco use, and high 
blood pressure) and injuries will require strong 
collaboration between the health sector and other sectors, 
such as education, labour, ﬁ scal, and more.68
Although the aim of this study was to address shortfalls 
in premature mortality and thus stress timely policy 
actions needed to meet targets, important limitations 
should be noted. First and foremost, national averages 
will always hide important heterogeneity in population 
health needs. Our study disaggregated results by age 
group but not by sex, geography, ethnic group, or other 
socioeconomic variables known to be highly relevant to 
fully understand and assess policy options. Second, most 
policies will invariably be met with some degree of 
system-wide constraints, most notably ﬁ nancing and 
staﬃ  ng restrictions. These might take years, if not 
decades, to overcome, and thus policy formulation might 
not easily move to the implementation phase in time to 
deliver substantial results by 2030. Finally, achieving 
gains in life expectancy will not guarantee healthier 
lifetimes free of disability and a more equitable 
distribution of health gains. Mental health problems as 
well as muscular-skeletal disabilities, many of which are 
highly prevalent in low-income populations, are not 
traditionally reﬂ ected in policies seeking to avert 
premature mortality. Finally, it is worth noting that the 
additional eﬀ ort needed to avert deaths across age groups 
and diseases is diﬀ erent and changing over time as new 
cost-eﬀ ective technologies are added to the health policy 
toolbox. Thus, the underlying assumption of reaching a 
40% reduction across causes provides only a reference 
rate of decrease and not necessarily the most desirable or 
eﬃ  cient pathways towards SDG3.
Mexico has achieved sustained progress in child, 
maternal, and infectious diseases-related mortality in the 
last three decades. However, it needs to adapt to the new 
health challenges in order to accelerate mortality 
reductions to attain SDG3. Urgent action is now needed 
to control NCDs and reduce fatal injuries, making a 
40% reduction in premature mortality by 2030 feasible 
and putting Mexico back on a track of substantial 
life expectancy convergence with better performing 
countries.
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